Disease on EC 1.1.1.149 - 20alpha-hydroxysteroid dehydrogenase
Please use the Disease Search for a specific query.
Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
20alpha-hydroxysteroid dehydrogenase deficiency
Regulation of progesterone levels during pregnancy and parturition by signal transducer and activator of transcription 5 and 20alpha-hydroxysteroid dehydrogenase.
Adenocarcinoma
AKR1C3 Inhibitor KV-37 Exhibits Antineoplastic Effects and Potentiates Enzalutamide in Combination Therapy in Prostate Adenocarcinoma Cells.
Adenocarcinoma
Aldo-keto reductase (AKR) 1C3: role in prostate disease and the development of specific inhibitors.
Adenocarcinoma
Aldo-keto reductase family 1 member C3 (AKR1C3) is expressed in adenocarcinoma and squamous cell carcinoma but not small cell carcinoma.
Adenocarcinoma
Elevated AKR1C3 expression promotes prostate cancer cell survival and prostate cell-mediated endothelial cell tube formation: implications for prostate cancer progression.
Adenocarcinoma
Expression of aldo-keto reductase family 1 member C3 (AKR1C3) in neuroendocrine tumors & adenocarcinomas of pancreas, gastrointestinal tract, and lung.
Adenocarcinoma
Suppressed expression of type 2 3alpha/type 5 17beta-hydroxysteroid dehydrogenase (AKR1C3) in endometrial hyperplasia and carcinoma.
Arthritis
Dysregulated androgen synthesis and anti-androgen resistance in advanced prostate cancer.
Astrocytoma
Inducible protection of human astrocytoma 1321N1 cells against hydrogen peroxide and aldehyde toxicity by 7-hydroxycoumarin is associated with the upregulation of aldo-keto reductases.
Blast Crisis
The aldo-keto reductase AKR1C3 contributes to 7,12-dimethylbenz(a)anthracene-3,4-dihydrodiol mediated oxidative DNA damage in myeloid cells: implications for leukemogenesis.
Breast Neoplasms
11?-Prostaglandin F2?, a bioactive metabolite catalyzed by AKR1C3, stimulates prostaglandin F receptor and induces slug expression in breast cancer.
Breast Neoplasms
A salicylic acid-based analogue discovered from virtual screening as a potent inhibitor of human 20alpha-hydroxysteroid dehydrogenase.
Breast Neoplasms
Activity and expression of progesterone metabolizing 5alpha-reductase, 20alpha-hydroxysteroid oxidoreductase and 3alpha(beta)-hydroxysteroid oxidoreductases in tumorigenic (MCF-7, MDA-MB-231, T-47D) and nontumorigenic (MCF-10A) human breast cancer cells.
Breast Neoplasms
AKR1C3 (type 5 17?-hydroxysteroid dehydrogenase/prostaglandin F synthase): Roles in malignancy and endocrine disorders.
Breast Neoplasms
AKR1C3 as a potential target for the inhibitory effect of dietary flavonoids.
Breast Neoplasms
AKR1C3 Inhibition Therapy in Castration-Resistant Prostate Cancer and Breast Cancer: Lessons from Responses to SN33638.
Breast Neoplasms
Aldo-keto reductase 1C3 (AKR1C3) is associated with the doxorubicin resistance in human breast cancer via PTEN Loss.
Breast Neoplasms
Aldo-keto reductase 1C3 expression in MCF-7 cells reveals roles in steroid hormone and prostaglandin metabolism that may explain its over-expression in breast cancer.
Breast Neoplasms
Alterations in estrogen signalling pathways upon acquisition of anthracycline resistance in breast tumor cells.
Breast Neoplasms
Analysis of 17beta-hydroxysteroid dehydrogenase types 5, 7, and 12 genetic sequence variants in breast cancer cases from French Canadian Families with high risk of breast and ovarian cancer.
Breast Neoplasms
Aryl hydrocarbon receptor counteracts pharmacological efficacy of doxorubicin via enhanced AKR1C3 expression in triple negative breast cancer cells.
Breast Neoplasms
Correlation of Aldo-Ketoreductase (AKR) 1C3 Genetic Variant with Doxorubicin Pharmacodynamics in Asian Breast Cancer Patients.
Breast Neoplasms
Cul3 overexpression depletes Nrf2 in breast cancer and is associated with sensitivity to carcinogens, to oxidative stress, and to chemotherapy.
Breast Neoplasms
Differential expression of type 2 3?/type 5 17?-hydroxysteroid dehydrogenase (AKR1C3) in tumors of the central nervous system.
Breast Neoplasms
Dutasteride affects progesterone metabolizing enzyme activity/expression in human breast cell lines resulting in suppression of cell proliferation and detachment.
Breast Neoplasms
Expression of progesterone metabolizing enzyme genes (AKR1C1, AKR1C2, AKR1C3, SRD5A1, SRD5A2) is altered in human breast carcinoma.
Breast Neoplasms
Genetic Variation in the Progesterone Receptor and Metabolism Pathways and Hormone Therapy in Relation to Breast Cancer Risk.
Breast Neoplasms
Hormone-related pathways and risk of breast cancer subtypes in African American women.
Breast Neoplasms
Inactivation of the anticancer drugs doxorubicin and oracin by aldo-keto reductase (AKR) 1C3.
Breast Neoplasms
Interactions between exposure to polycyclic aromatic hydrocarbons and xenobiotic metabolism genes, and risk of breast cancer.
Breast Neoplasms
Paracrine-stimulated gene expression profile favors estradiol production in breast tumors.
Breast Neoplasms
Polymorphism Thr160Thr in SRD5A1, involved in the progesterone metabolism, modifies postmenopausal breast cancer risk associated with menopausal hormone therapy.
Breast Neoplasms
Pyrithione-based ruthenium complexes as inhibitors of aldo-keto reductase 1C enzymes and anticancer agents.
Breast Neoplasms
Selective AKR1C3 inhibitors do not recapitulate the anti-leukaemic activities of the pan-AKR1C inhibitor medroxyprogesterone acetate.
Breast Neoplasms
Selective loss of AKR1C1 and AKR1C2 in breast cancer and their potential effect on progesterone signaling.
Breast Neoplasms
Stromal markers AKR1C1 and AKR1C2 are prognostic factors in primary human breast cancer.
Breast Neoplasms
Synthesis, antitumor activity and in silico analyses of amino acid derivatives of artepillin C, drupanin and baccharin from green propolis.
Breast Neoplasms
The Activity of SN33638, an Inhibitor of AKR1C3, on Testosterone and 17?-Estradiol Production and Function in Castration-Resistant Prostate Cancer and ER-Positive Breast Cancer.
Breast Neoplasms
The role of progesterone metabolites in breast cancer: potential for new diagnostics and therapeutics.
Breast Neoplasms
Type 5 17-hydroxysteroid dehydrogenase/prostaglandin F synthase (AKR1C3) inhibition and potential anti-proliferative activity of cholest-4-ene-3,6-dione in MCF-7 breast cancer cells.
Breast Neoplasms
Type 5 17beta-hydroxysteroid dehydrogenase/prostaglandin F synthase (AKR1C3): role in breast cancer and inhibition by non-steroidal anti-inflammatory drug analogs.
Carcinogenesis
AKR1C3, a crucial androgenic enzyme in prostate cancer, promotes epithelial-mesenchymal transition and metastasis through activating ERK signaling.
Carcinogenesis
Basal and Regulatory Promoter Studies of the AKR1C3 Gene in Relation to Prostate Cancer.
Carcinogenesis
Design and development of novel inhibitors of aldo-ketoreductase 1C1 as potential lead molecules in treatment of breast cancer.
Carcinoma
11?-Prostaglandin F2?, a bioactive metabolite catalyzed by AKR1C3, stimulates prostaglandin F receptor and induces slug expression in breast cancer.
Carcinoma
AKR1C1 controls cisplatin-resistance in head and neck squamous cell carcinoma through cross-talk with the STAT1/3 signaling pathway.
Carcinoma
Aldo-keto reductase 1C3 is overexpressed in skin squamous cell carcinoma (SCC) and affects SCC growth via prostaglandin metabolism.
Carcinoma
Aldo-keto reductase family 1 member C3 (AKR1C3) is expressed in adenocarcinoma and squamous cell carcinoma but not small cell carcinoma.
Carcinoma
CIAPIN1 and ABCA13 are markers of poor survival in metastatic ovarian serous carcinoma.
Carcinoma
Differential expression of type 2 3?/type 5 17?-hydroxysteroid dehydrogenase (AKR1C3) in tumors of the central nervous system.
Carcinoma
Elevated expression of AKR1C3 increases resistance of cancer cells to ionizing radiation via modulation of oxidative stress.
Carcinoma
Expression of AKR1C3 in renal cell carcinoma, papillary urothelial carcinoma, and Wilms' tumor.
Carcinoma
Expression of aldo-keto reductase family 1 member C3 (AKR1C3) in neuroendocrine tumors & adenocarcinomas of pancreas, gastrointestinal tract, and lung.
Carcinoma
Increased expression of type 2 3{alpha}-hydroxysteroid dehydrogenase/type 5 17{beta}-hydroxysteroid dehydrogenase (AKR1C3) and its relationship with androgen receptor in prostate carcinoma.
Carcinoma
Integration of HPV6 and Downregulation of AKR1C3 Expression Mark Malignant Transformation in a Patient with Juvenile-Onset Laryngeal Papillomatosis.
Carcinoma
Isoform-specific induction of a human aldo-keto reductase by polycyclic aromatic hydrocarbons (PAHs), electrophiles, and oxidative stress: implications for the alternative pathway of PAH activation catalyzed by human dihydrodiol dehydrogenase.
Carcinoma
Mefenamic acid enhances anticancer drug sensitivity via inhibition of aldo-keto reductase 1C enzyme activity.
Carcinoma
Methyl jasmonate enhances the radiation sensitivity of esophageal carcinoma cells by inhibiting the 11-ketoprostaglandin reductase activity of AKR1C3.
Carcinoma
Stromal markers AKR1C1 and AKR1C2 are prognostic factors in primary human breast cancer.
Carcinoma
The bioreductive prodrug PR-104A is activated under aerobic conditions by human aldo-keto reductase 1C3.
Carcinoma
The CCAAT box binding transcription factor, nuclear factor-Y (NF-Y) regulates transcription of human aldo-keto reductase 1C1 (AKR1C1) gene.
Carcinoma
The roles of AKR1C1 and AKR1C2 in ethyl-3,4-dihydroxybenzoateinduced esophageal squamous cell carcinoma cell death.
Carcinoma, Ductal
Paracrine-stimulated gene expression profile favors estradiol production in breast tumors.
Carcinoma, Ductal
Type 5 17beta-hydroxysteroid dehydrogenase/prostaglandin F synthase (AKR1C3): role in breast cancer and inhibition by non-steroidal anti-inflammatory drug analogs.
Carcinoma, Hepatocellular
A Positive Feedback Loop of AKR1C3-Mediated Activation of NF-?B and STAT3 Facilitates Proliferation and Metastasis in Hepatocellular Carcinoma.
Carcinoma, Hepatocellular
Diagnostic and prognostic values of AKR1C3 and AKR1D1 in hepatocellular carcinoma.
Carcinoma, Hepatocellular
Gene expression profiles of HeLa Cells impacted by hepatitis C virus non-structural protein NS4B.
Carcinoma, Hepatocellular
Isoform-specific induction of a human aldo-keto reductase by polycyclic aromatic hydrocarbons (PAHs), electrophiles, and oxidative stress: implications for the alternative pathway of PAH activation catalyzed by human dihydrodiol dehydrogenase.
Carcinoma, Hepatocellular
PR-104 plus sorafenib in patients with advanced hepatocellular carcinoma.
Carcinoma, Hepatocellular
Pre-clinical activity of PR-104 as monotherapy and in combination with sorafenib in hepatocellular carcinoma.
Carcinoma, Hepatocellular
The role of aryl hydrocarbon receptor in regulation of enzymes involved in metabolic activation of polycyclic aromatic hydrocarbons in a model of rat liver progenitor cells.
Carcinoma, Intraductal, Noninfiltrating
Paracrine-stimulated gene expression profile favors estradiol production in breast tumors.
Carcinoma, Non-Small-Cell Lung
AKR1C1 Activates STAT3 to Promote the Metastasis of Non-Small Cell Lung Cancer.
Carcinoma, Non-Small-Cell Lung
AKR1C3 and ?-catenin expression in non-small cell lung cancer and relationship with radiation resistance.
Carcinoma, Non-Small-Cell Lung
Aldo-keto reductase family 1 member C3 (AKR1C3) is expressed in adenocarcinoma and squamous cell carcinoma but not small cell carcinoma.
Carcinoma, Non-Small-Cell Lung
The bioreductive prodrug PR-104A is activated under aerobic conditions by human aldo-keto reductase 1C3.
Carcinoma, Non-Small-Cell Lung
The SIRT2-mediated deacetylation of AKR1C1 is required for suppressing its pro-metastasis function in Non-Small Cell Lung Cancer.
Carcinoma, Renal Cell
Expression of AKR1C3 in renal cell carcinoma, papillary urothelial carcinoma, and Wilms' tumor.
Carcinoma, Small Cell
Aldo-keto reductase family 1 member C3 (AKR1C3) is expressed in adenocarcinoma and squamous cell carcinoma but not small cell carcinoma.
Carcinoma, Small Cell
Expression of aldo-keto reductase family 1 member C3 (AKR1C3) in neuroendocrine tumors & adenocarcinomas of pancreas, gastrointestinal tract, and lung.
Carcinoma, Squamous Cell
AKR1C1 controls cisplatin-resistance in head and neck squamous cell carcinoma through cross-talk with the STAT1/3 signaling pathway.
Carcinoma, Squamous Cell
Aldo-keto reductase 1C3 is overexpressed in skin squamous cell carcinoma (SCC) and affects SCC growth via prostaglandin metabolism.
Carcinoma, Squamous Cell
Aldo-keto reductase family 1 member C3 (AKR1C3) is expressed in adenocarcinoma and squamous cell carcinoma but not small cell carcinoma.
Carcinoma, Squamous Cell
Expression of aldo-keto reductase family 1 member C3 (AKR1C3) in neuroendocrine tumors & adenocarcinomas of pancreas, gastrointestinal tract, and lung.
Carcinoma, Squamous Cell
Mefenamic acid enhances anticancer drug sensitivity via inhibition of aldo-keto reductase 1C enzyme activity.
Cardiomyopathies
Inactivation of the anticancer drugs doxorubicin and oracin by aldo-keto reductase (AKR) 1C3.
Choriocarcinoma
AKR1C3 overexpression mediates methotrexate resistance in choriocarcinoma cells.
Colonic Neoplasms
A Novel Ferroptosis Related Gene Signature for Prognosis Prediction in Patients With Colon Cancer.
Colonic Neoplasms
Pathophysiological roles of aldo-keto reductases (AKR1C1 and AKR1C3) in development of cisplatin resistance in human colon cancers.
Colonic Neoplasms
Proteasome inhibitors MG-132 and bortezomib induce AKR1C1, AKR1C3, AKR1B1, and AKR1B10 in human colon cancer cell lines SW-480 and HT-29.
Colonic Neoplasms
Significance of aldo-keto reductase 1C3 and ATP-binding cassette transporter B1 in gain of irinotecan resistance in colon cancer cells.
Colonic Neoplasms
Sulforaphane Preconditioning Sensitizes Human Colon Cancer Cells towards the Bioreductive Anticancer Prodrug PR-104A.
Colorectal Neoplasms
Buparlisib is a novel inhibitor of daunorubicin reduction mediated by aldo-keto reductase 1C3.
Colorectal Neoplasms
Expression of AKR1C3 and CNN3 as markers for detection of lymph node metastases in colorectal cancer.
Colorectal Neoplasms
Olaparib Synergizes the Anticancer Activity of Daunorubicin via Interaction with AKR1C3.
Deglutition Disorders
Changes in global gene expression indicate disordered autophagy, apoptosis and inflammatory processes and downregulation of cytoskeletal signalling and neuronal development in patients with Niemann-Pick C disease.
Dehydration
Aldo-keto reductase 1C3 is overexpressed in skin squamous cell carcinoma (SCC) and affects SCC growth via prostaglandin metabolism.
Dysarthria
Changes in global gene expression indicate disordered autophagy, apoptosis and inflammatory processes and downregulation of cytoskeletal signalling and neuronal development in patients with Niemann-Pick C disease.
Endometrial Hyperplasia
Differential expression of type 2 3?/type 5 17?-hydroxysteroid dehydrogenase (AKR1C3) in tumors of the central nervous system.
Endometrial Neoplasms
A salicylic acid-based analogue discovered from virtual screening as a potent inhibitor of human 20alpha-hydroxysteroid dehydrogenase.
Endometrial Neoplasms
AKR1C1 and AKR1C3 may determine progesterone and estrogen ratios in endometrial cancer.
Endometrial Neoplasms
AKR1C3 as a potential target for the inhibitory effect of dietary flavonoids.
Endometrial Neoplasms
AKR1C3 Is Associated with Better Survival of Patients with Endometrial Carcinomas.
Endometrial Neoplasms
Derivatives of pyrimidine, phthalimide and anthranilic acid as inhibitors of human hydroxysteroid dehydrogenase AKR1C1.
Endometrial Neoplasms
Differential expression of type 2 3?/type 5 17?-hydroxysteroid dehydrogenase (AKR1C3) in tumors of the central nervous system.
Endometrial Neoplasms
Mechanism of progestin resistance in endometrial precancer/cancer through Nrf2-AKR1C1 pathway.
Endometriosis
A salicylic acid-based analogue discovered from virtual screening as a potent inhibitor of human 20alpha-hydroxysteroid dehydrogenase.
Endometriosis
Aldo-keto reductase 1C3 - assessment as a new target for the treatment of endometriosis.
Endometriosis
Aldo-keto reductase activity after diethylhexyl phthalate exposure in eutopic and ectopic endometrial cells.
Endometriosis
Aldo-keto reductases AKR1C1, AKR1C2 and AKR1C3 may enhance progesterone metabolism in ovarian endometriosis.
Endometriosis
Derivatives of pyrimidine, phthalimide and anthranilic acid as inhibitors of human hydroxysteroid dehydrogenase AKR1C1.
Endometriosis
Expression of AKR1B1, AKR1C3 and other genes of prostaglandin F2? biosynthesis and action in ovarian endometriosis tissue and in model cell lines.
Endometriosis
Expression of human aldo-keto reductase 1C2 in cell lines of peritoneal endometriosis: Potential implications in metabolism of progesterone and dydrogesterone and inhibition by progestins.
Endometriosis
Progestins as inhibitors of the human 20-ketosteroid reductases, AKR1C1 and AKR1C3.
Epilepsy
A salicylic acid-based analogue discovered from virtual screening as a potent inhibitor of human 20alpha-hydroxysteroid dehydrogenase.
Epilepsy
Derivatives of pyrimidine, phthalimide and anthranilic acid as inhibitors of human hydroxysteroid dehydrogenase AKR1C1.
Epilepsy
Expression of 5alpha-reductase and 3alpha-hydroxisteroid oxidoreductase in the hippocampus of patients with chronic temporal lobe epilepsy.
Epilepsy, Temporal Lobe
Expression of 5alpha-reductase and 3alpha-hydroxisteroid oxidoreductase in the hippocampus of patients with chronic temporal lobe epilepsy.
Esophageal Neoplasms
Overexpression of AKR1C3 significantly enhances human prostate cancer cells resistance to radiation.
Esophageal Squamous Cell Carcinoma
The roles of AKR1C1 and AKR1C2 in ethyl-3,4-dihydroxybenzoateinduced esophageal squamous cell carcinoma cell death.
Fetal Resorption
An enzymologic study of corpora lutea in early pregnant rats treated with abortifacient agents.
Glaucoma
Transcriptional profiling analysis predicts potential biomarkers for glaucoma: HGF, AKR1B10 and AKR1C3.
Glioma
Identification of hypoxia-induced genes in a malignant glioma cell line (U-251) by cDNA microarray analysis.
Hepatitis B
Hepatitis B Virus X Protein Up-Regulates AKR1C1 Expression Through Nuclear Factor-Y in Human Hepatocarcinoma Cells.
Herpes Zoster
Histochemical studies of 3 beta- and 20alpha-hydroxysteroiddehydrogenase in the adrenals and ovaries of the nu/nu mouse.
Herpes Zoster
Type 5 17{beta}-hydroxysteroid dehydrogenase (AKR1C3) contributes to testosterone production in adrenal reticularis.
Hyperglycemia
Transcript Levels of Aldo-Keto Reductase Family 1 Subfamily C (AKR1C) Are Increased in Prostate Tissue of Patients with Type 2 Diabetes.
Hypospadias
Fine mapping analysis confirms and strengthens linkage of four chromosomal regions in familial hypospadias.
Keloid
The role of aldo-keto reductase 1C3 (AKR1C3)-mediated prostaglandin D2 (PGD2) metabolism in keloids.
Kidney Neoplasms
Expression of AKR1C3 in renal cell carcinoma, papillary urothelial carcinoma, and Wilms' tumor.
Leprosy
Reanalysis and integration of public microarray datasets reveals novel host genes modulated in leprosy.
Leukemia
Identification of aldo-keto reductases as NRF2-target marker genes in human cells.
Leukemia
Maternal and offspring genetic variants of AKR1C3 and the risk of childhood leukemia.
Leukemia
Morpholylureas are a new class of potent and selective inhibitors of the type 5 17-?-hydroxysteroid dehydrogenase (AKR1C3).
Leukemia
Potent and Highly Selective Aldo-Keto Reductase 1C3 (AKR1C3) Inhibitors Act as Chemotherapeutic Potentiators in Acute Myeloid Leukemia and T-Cell Acute Lymphoblastic Leukemia.
Leukemia
Synthesis and structure-activity relationships for 1-(4-(piperidin-1-ylsulfonyl)phenyl)pyrrolidin-2-ones as novel non-carboxylate inhibitors of the aldo-keto reductase enzyme AKR1C3.
Leukemia
The aldo-keto reductase AKR1C3 contributes to 7,12-dimethylbenz(a)anthracene-3,4-dihydrodiol mediated oxidative DNA damage in myeloid cells: implications for leukemogenesis.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
The aldo-keto reductase AKR1C3 contributes to 7,12-dimethylbenz(a)anthracene-3,4-dihydrodiol mediated oxidative DNA damage in myeloid cells: implications for leukemogenesis.
Leukemia, Myeloid
Development of nonsteroidal anti-inflammatory drug analogs and steroid carboxylates selective for human aldo-keto reductase isoforms: potential antineoplastic agents that work independently of cyclooxygenase isozymes.
Leukemia, Myeloid
The aldo-keto reductase AKR1C3 is a novel suppressor of cell differentiation that provides a plausible target for the non-cyclooxygenase-dependent antineoplastic actions of nonsteroidal anti-inflammatory drugs.
Leukemia, Myeloid, Acute
AKR1C3 (type 5 17?-hydroxysteroid dehydrogenase/prostaglandin F synthase): Roles in malignancy and endocrine disorders.
Leukemia, Myeloid, Acute
Hypoxia triggers major metabolic changes in AML cells without altering indomethacin-induced TCA cycle deregulation.
Leukemia, Myeloid, Acute
Knockdown of AKR1C3 exposes a potential epigenetic susceptibility in prostate cancer cells.
Leukemia, Myeloid, Acute
Selective AKR1C3 Inhibitors Potentiate Chemotherapeutic Activity in Multiple Acute Myeloid Leukemia (AML) Cell Lines.
Leukemia, Myeloid, Acute
The aldo-keto reductase AKR1C3 contributes to 7,12-dimethylbenz(a)anthracene-3,4-dihydrodiol mediated oxidative DNA damage in myeloid cells: implications for leukemogenesis.
Lipedema
Aldo-Keto Reductase 1C1 (AKR1C1) as the First Mutated Gene in a Family with Nonsyndromic Primary Lipedema.
Liver Diseases, Alcoholic
Major differences exist in the function and tissue-specific expression of human aflatoxin B1 aldehyde reductase and the principal human aldo-keto reductase AKR1 family members.
Liver Neoplasms
A novel AKR1C3 specific prodrug TH3424 with potent anti-tumor activity in liver cancer.
Liver Neoplasms
AKR1C1-3, notably AKR1C3, are distinct biomarkers for liver cancer diagnosis and prognosis: Database mining in malignancies.
Liver Neoplasms
An AKR1C3-specific prodrug with potent anti-tumor activities against T-ALL.
Lung Neoplasms
AKR1C1 Activates STAT3 to Promote the Metastasis of Non-Small Cell Lung Cancer.
Lung Neoplasms
AKR1C3 and ?-catenin expression in non-small cell lung cancer and relationship with radiation resistance.
Lung Neoplasms
Aldo-keto reductase 1C3 may be a new radioresistance marker in non-small-cell lung cancer.
Lung Neoplasms
Exposure to airborne PM2.5 suppresses microRNA expression and deregulates target oncogenes that cause neoplastic transformation in NIH3T3 cells.
Lung Neoplasms
Finding Genes Discriminating Smokers from Non-smokers by Applying a Growing Self-organizing Clustering Method to Large Airway Epithelium Cell Microarray Data.
Lung Neoplasms
High expression of AKR1C1 is associated with proliferation and migration of small-cell lung cancer cells.
Lung Neoplasms
Overexpression of AKR1C3 significantly enhances human prostate cancer cells resistance to radiation.
Lung Neoplasms
Oxidative damage-related genes AKR1C3 and OGG1 modulate risks for lung cancer due to exposure to PAH-rich coal combustion emissions.
Lung Neoplasms
Roles of aldo-keto reductase 1B10 and 1C3 and ATP-binding cassette transporter in docetaxel tolerance.
Lung Neoplasms
The SIRT2-mediated deacetylation of AKR1C1 is required for suppressing its pro-metastasis function in Non-Small Cell Lung Cancer.
Lung Neoplasms
Wentilactone A induces cell apoptosis by targeting AKR1C1 gene via the IGF-1R/IRS1/PI3K/AKT/Nrf2/FLIP/Caspase-3 signaling pathway in small cell lung cancer.
Lymphatic Metastasis
Expression of AKR1C3 and CNN3 as markers for detection of lymph node metastases in colorectal cancer.
Lymphoma, Non-Hodgkin
Genetic Polymorphisms in Oxidative Stress Pathway Genes and Modification of BMI and Risk of Non-Hodgkin Lymphoma.
Lymphoma, Non-Hodgkin
Genetic polymorphisms in the oxidative stress pathway and susceptibility to non-Hodgkin lymphoma.
Medulloblastoma
Differential expression of type 2 3?/type 5 17?-hydroxysteroid dehydrogenase (AKR1C3) in tumors of the central nervous system.
Meningioma
Differential expression of type 2 3?/type 5 17?-hydroxysteroid dehydrogenase (AKR1C3) in tumors of the central nervous system.
Metabolic Diseases
Regulation of human aldoketoreductase 1C3 (AKR1C3) gene expression in the adipose tissue.
Metabolic Syndrome
Regulation of human aldoketoreductase 1C3 (AKR1C3) gene expression in the adipose tissue.
Neoplasm Metastasis
A Positive Feedback Loop of AKR1C3-Mediated Activation of NF-?B and STAT3 Facilitates Proliferation and Metastasis in Hepatocellular Carcinoma.
Neoplasm Metastasis
AKR1C1 Activates STAT3 to Promote the Metastasis of Non-Small Cell Lung Cancer.
Neoplasm Metastasis
AKR1C3, a crucial androgenic enzyme in prostate cancer, promotes epithelial-mesenchymal transition and metastasis through activating ERK signaling.
Neoplasm Metastasis
Aldo-keto reductase 1C1 induced by interleukin-1? mediates the invasive potential and drug resistance of metastatic bladder cancer cells.
Neoplasm Metastasis
Circulating tumor cells mirror bone metastatic phenotype in prostate cancer.
Neoplasm Metastasis
Clinical implications of aldo-keto reductase family 1 member C3 and its relationship with lipocalin 2 in cancer of the uterine cervix.
Neoplasm Metastasis
Contribution of Adrenal Glands to Intra-tumor Androgens and Growth of Castration Resistant Prostate Cancer.
Neoplasm Metastasis
Expression of AKR1C3 and CNN3 as markers for detection of lymph node metastases in colorectal cancer.
Neoplasm Metastasis
Inhibitory Interplay of SULT2B1b Sulfotransferase with AKR1C3 Aldo-keto Reductase in Prostate Cancer.
Neoplasm Metastasis
Loss of AKR1C1 is a good prognostic factor in advanced NPC cases and increases chemosensitivity to cisplatin in NPC cells.
Neoplasm Metastasis
Testosterone accumulation in prostate cancer cells is enhanced by facilitated diffusion.
Neoplasms
A low carbohydrate, high protein diet suppresses intratumoral androgen synthesis and slows castration-resistant prostate tumor growth in mice.
Neoplasms
A Mansonone Derivative Coupled with Monoclonal Antibody 4D5-Modified Chitosan Inhibit AKR1C3 to Treat Castration-Resistant Prostate Cancer.
Neoplasms
A novel AKR1C3 specific prodrug TH3424 with potent anti-tumor activity in liver cancer.
Neoplasms
A novel selective AKR1C3-activated prodrug AST-3424/OBI-3424 exhibits broad anti-tumor activity.
Neoplasms
A Positive Feedback Loop of AKR1C3-Mediated Activation of NF-?B and STAT3 Facilitates Proliferation and Metastasis in Hepatocellular Carcinoma.
Neoplasms
A salicylic acid-based analogue discovered from virtual screening as a potent inhibitor of human 20alpha-hydroxysteroid dehydrogenase.
Neoplasms
Activation of AKR1C1/ER? induces apoptosis by downregulation of c-FLIP in prostate cancer cells: A prospective therapeutic opportunity.
Neoplasms
AKR1C1 Contributes to Cervical Cancer Progression via Regulating TWIST1 Expression.
Neoplasms
AKR1C1-3, notably AKR1C3, are distinct biomarkers for liver cancer diagnosis and prognosis: Database mining in malignancies.
Neoplasms
AKR1C3 (type 5 17?-hydroxysteroid dehydrogenase/prostaglandin F synthase): Roles in malignancy and endocrine disorders.
Neoplasms
AKR1C3 Is Associated with Better Survival of Patients with Endometrial Carcinomas.
Neoplasms
Aldo-keto reductase (AKR) 1C3: role in prostate disease and the development of specific inhibitors.
Neoplasms
Aldo-keto reductase 1C1 induced by interleukin-1? mediates the invasive potential and drug resistance of metastatic bladder cancer cells.
Neoplasms
Aldo-keto reductase 1C3 (AKR1C3) is associated with the doxorubicin resistance in human breast cancer via PTEN Loss.
Neoplasms
Aldo-keto reductase 1C3 (AKR1C3): a missing piece of the puzzle in the dinaciclib interaction profile.
Neoplasms
Aldo-keto reductase 1C3 is overexpressed in skin squamous cell carcinoma (SCC) and affects SCC growth via prostaglandin metabolism.
Neoplasms
Aldo-Keto Reductase 1C3 Mediates Chemotherapy Resistance in Esophageal Adenocarcinoma via ROS Detoxification.
Neoplasms
Aldo-keto reductase family 1 member C1 regulates the osteogenic differentiation of human ASCs by targeting the progesterone receptor.
Neoplasms
An indomethacin analogue, N-(4-chlorobenzoyl)-melatonin, is a selective inhibitor of aldo-keto reductase 1C3 (type 2 3alpha-HSD, type 5 17beta-HSD, and prostaglandin F synthase), a potential target for the treatment of hormone dependent and hormone independent malignancies.
Neoplasms
Androgenic and estrogenic 17beta-hydroxysteroid dehydrogenase/17-ketosteroid reductase in human ovarian epithelial tumors: evidence for the type 1, 2 and 5 isoforms.
Neoplasms
Anthracycline resistance mediated by reductive metabolism in cancer cells: the role of aldo-keto reductase 1C3.
Neoplasms
Avasimibe Dampens Cholangiocarcinoma Progression by Inhibiting FoxM1-AKR1C1 Signaling.
Neoplasms
Biological role of aldo-keto reductases in retinoic Acid biosynthesis and signaling.
Neoplasms
Bruton's Tyrosine Kinase Inhibitors Ibrutinib and Acalabrutinib Counteract Anthracycline Resistance in Cancer Cells Expressing AKR1C3.
Neoplasms
Characterization of a highly specific monoclonal antibody against human aldo-keto reductase AKR1C3.
Neoplasms
Characterization of a monoclonal antibody for human aldo-keto reductase AKR1C3 (type 2 3alpha-hydroxysteroid dehydrogenase/type 5 17beta-hydroxysteroid dehydrogenase); immunohistochemical detection in breast and prostate.
Neoplasms
Consecutive Prostate Cancer Specimens Revealed Increased Aldo?Keto Reductase Family 1 Member C3 Expression with Progression to Castration-Resistant Prostate Cancer.
Neoplasms
Contribution of Adrenal Glands to Intra-tumor Androgens and Growth of Castration Resistant Prostate Cancer.
Neoplasms
Crystal structures of AKR1C3 containing an N-(aryl)amino-benzoate inhibitor and a bifunctional AKR1C3 inhibitor and androgen receptor antagonist. Therapeutic leads for castrate resistant prostate cancer.
Neoplasms
Crystal structures of prostaglandin D(2) 11-ketoreductase (AKR1C3) in complex with the nonsteroidal anti-inflammatory drugs flufenamic acid and indomethacin.
Neoplasms
Crystal Structures of Three Classes of Non-Steroidal Anti-Inflammatory Drugs in Complex with Aldo-Keto Reductase 1C3.
Neoplasms
Current advances in intratumoral androgen metabolism in castration-resistant prostate cancer.
Neoplasms
Diagnostic and prognostic values of AKR1C3 and AKR1D1 in hepatocellular carcinoma.
Neoplasms
Differential expression of type 2 3?/type 5 17?-hydroxysteroid dehydrogenase (AKR1C3) in tumors of the central nervous system.
Neoplasms
Dual Inhibitory Action of a Novel AKR1C3 Inhibitor on Both Full-Length AR and the Variant AR-V7 in Enzalutamide Resistant Metastatic Castration Resistant Prostate Cancer.
Neoplasms
Elevated AKR1C3 expression promotes prostate cancer cell survival and prostate cell-mediated endothelial cell tube formation: implications for prostate cancer progression.
Neoplasms
Elevated expression of AKR1C3 increases resistance of cancer cells to ionizing radiation via modulation of oxidative stress.
Neoplasms
Expression of aldo-keto reductase family 1 member C3 (AKR1C3) in neuroendocrine tumors & adenocarcinomas of pancreas, gastrointestinal tract, and lung.
Neoplasms
Expression of androgen receptor through androgen-converting enzymes is associated with biological aggressiveness in prostate cancer.
Neoplasms
High expression of AKR1C1 is associated with proliferation and migration of small-cell lung cancer cells.
Neoplasms
Impaired dihydrotestosterone catabolism in human prostate cancer: critical role of AKR1C2 as a pre-receptor regulator of androgen receptor signaling.
Neoplasms
Inactivation of the anticancer drugs doxorubicin and oracin by aldo-keto reductase (AKR) 1C3.
Neoplasms
Induction of neoplastic transformation by ectopic expression of human aldo-keto reductase 1C isoforms in NIH3T3 cells.
Neoplasms
Inhibitors of type 5 17?-hydroxysteroid dehydrogenase (AKR1C3): Overview and structural insights.
Neoplasms
Initial testing of the hypoxia-activated prodrug PR-104 by the pediatric preclinical testing program.
Neoplasms
Intracrine androgens and AKR1C3 activation confer resistance to enzalutamide in prostate cancer.
Neoplasms
Knockdown of AKR1C3 exposes a potential epigenetic susceptibility in prostate cancer cells.
Neoplasms
Localization and altered expression of AKR1C family members in human ovarian tissues.
Neoplasms
Long-term in vitro treatment of human glioblastoma cells with temozolomide increases resistance in vivo through up-regulation of GLUT transporter and aldo-keto reductase enzyme AKR1C expression.
Neoplasms
Loss of AKR1C1 is a good prognostic factor in advanced NPC cases and increases chemosensitivity to cisplatin in NPC cells.
Neoplasms
Mefenamic acid enhances anticancer drug sensitivity via inhibition of aldo-keto reductase 1C enzyme activity.
Neoplasms
Modulated expression of genes encoding estrogen metabolizing enzymes by G1-phase cyclin-dependent kinases 6 and 4 in human breast cancer cells.
Neoplasms
Morpholylureas are a new class of potent and selective inhibitors of the type 5 17-?-hydroxysteroid dehydrogenase (AKR1C3).
Neoplasms
New cyclopentane derivatives as inhibitors of steroid metabolizing enzymes AKR1C1 and AKR1C3.
Neoplasms
Overexpression of AKR1C3 significantly enhances human prostate cancer cells resistance to radiation.
Neoplasms
Progesterone metabolism in normal human endometrium during the menstrual cycle and in endometrial carcinoma.
Neoplasms
Quantitative analysis of the human AKR family members in cancer cell lines using the mTRAQ/MRM approach.
Neoplasms
Reductive metabolism of the dinitrobenzamide mustard anticancer prodrug PR-104 in mice.
Neoplasms
Selective loss of AKR1C1 and AKR1C2 in breast cancer and their potential effect on progesterone signaling.
Neoplasms
Steroidogenic Enzyme AKR1C3 Is a Novel Androgen Receptor-Selective Coactivator that Promotes Prostate Cancer Growth.
Neoplasms
Stromal markers AKR1C1 and AKR1C2 are prognostic factors in primary human breast cancer.
Neoplasms
Sulforaphane Preconditioning Sensitizes Human Colon Cancer Cells towards the Bioreductive Anticancer Prodrug PR-104A.
Neoplasms
Synthesis and structure-activity relationships for 1-(4-(piperidin-1-ylsulfonyl)phenyl)pyrrolidin-2-ones as novel non-carboxylate inhibitors of the aldo-keto reductase enzyme AKR1C3.
Neoplasms
Testosterone accumulation in prostate cancer cells is enhanced by facilitated diffusion.
Neoplasms
The Activity of SN33638, an Inhibitor of AKR1C3, on Testosterone and 17?-Estradiol Production and Function in Castration-Resistant Prostate Cancer and ER-Positive Breast Cancer.
Neoplasms
The bioreductive prodrug PR-104A is activated under aerobic conditions by human aldo-keto reductase 1C3.
Neoplasms
The CCAAT box binding transcription factor, nuclear factor-Y (NF-Y) regulates transcription of human aldo-keto reductase 1C1 (AKR1C1) gene.
Neoplasms
The role of cytochromes p450 and aldo-keto reductases in prognosis of breast carcinoma patients.
Neoplasms
The SIRT2-mediated deacetylation of AKR1C1 is required for suppressing its pro-metastasis function in Non-Small Cell Lung Cancer.
Neoplasms
The Steroidogenic Enzyme AKR1C3 Regulates Stability of the Ubiquitin Ligase Siah2 in Prostate Cancer Cells.
Neoplasms
Tissue distribution of human AKR1C3 and rat homolog in the adult genitourinary system.
Neoplasms
TMPRSS2-ERG fusions confer efficacy of enzalutamide in an in vivo bone tumor growth model.
Neoplasms
Tsumura-Suzuki obese diabetic mice-derived hepatic tumors closely resemble human hepatocellular carcinomas in metabolism-related genes expression and bile acid accumulation.
Neoplasms
Upregulation of AKR1C1 and AKR1C3 expression in OPSCC with integrated HPV16 and HPV-negative tumors is an indicator of poor prognosis.
Nervous System Diseases
A salicylic acid-based analogue discovered from virtual screening as a potent inhibitor of human 20alpha-hydroxysteroid dehydrogenase.
Neuralgia
The biological activity of 3alpha-hydroxysteroid oxido-reductase in the spinal cord regulates thermal and mechanical pain thresholds after sciatic nerve injury.
Neurilemmoma
Differential expression of type 2 3?/type 5 17?-hydroxysteroid dehydrogenase (AKR1C3) in tumors of the central nervous system.
Obesity, Abdominal
Expression and activity of 20alpha-hydroxysteroid dehydrogenase (AKR1C1) in abdominal subcutaneous and omental adipose tissue in women.
Obesity, Abdominal
Intra-adipose sex steroid metabolism and body fat distribution in idiopathic human obesity.
Ovarian Neoplasms
AKR1C3 Is Associated with Better Survival of Patients with Endometrial Carcinomas.
Papilloma
Integration of HPV6 and Downregulation of AKR1C3 Expression Mark Malignant Transformation in a Patient with Juvenile-Onset Laryngeal Papillomatosis.
Peripheral Nerve Injuries
Selective regulation of 3 alpha-hydroxysteroid oxido-reductase expression in dorsal root ganglion neurons: a possible mechanism to cope with peripheral nerve injury-induced chronic pain.
Polycystic Ovary Syndrome
AKR1C3 (type 5 17?-hydroxysteroid dehydrogenase/prostaglandin F synthase): Roles in malignancy and endocrine disorders.
Polycystic Ovary Syndrome
Effect of insulin on AKR1C3 expression in female adipose tissue: in-vivo and in-vitro study of adipose androgen generation in polycystic ovary syndrome.
Pre-Eclampsia
Role of AKR1C3 in renal injury and glibenclamide is anti-inflammatory in preeclamptic rats.
Pre-Eclampsia
[Microarray analysis of differentially expressed genes in peripheral leucocytes derived from severe preeclampsia and normotensive pregnancies]
Precursor Cell Lymphoblastic Leukemia-Lymphoma
AKR1C3 is a biomarker of sensitivity to PR-104 in preclinical models of T-cell acute lymphoblastic leukemia.
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
A novel fluorometric assay for aldo-keto reductase 1C3 predicts metabolic activation of the nitrogen mustard prodrug PR-104A in human leukaemia cells.
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
AKR1C3 is a biomarker of sensitivity to PR-104 in preclinical models of T-cell acute lymphoblastic leukemia.
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
An AKR1C3-specific prodrug with potent anti-tumor activities against T-ALL.
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
OBI-3424, a Novel AKR1C3-Activated Prodrug, Exhibits Potent Efficacy against Preclinical Models of T-ALL.
Premature Birth
A salicylic acid-based analogue discovered from virtual screening as a potent inhibitor of human 20alpha-hydroxysteroid dehydrogenase.
Prostatic Neoplasms
3-(3,4-Dihydroisoquinolin-2(1H)-ylsulfonyl)benzoic Acids: Highly Potent and Selective Inhibitors of the Type 5 17-?-Hydroxysteroid Dehydrogenase AKR1C3.
Prostatic Neoplasms
3D-QSAR studies of 3-(3,4-dihydroisoquinolin-2(1H)-ylsulfonyl)benzoic acids as AKR1C3 inhibitors: Highlight the importance of molecular docking in conformation generation.
Prostatic Neoplasms
A Mansonone Derivative Coupled with Monoclonal Antibody 4D5-Modified Chitosan Inhibit AKR1C3 to Treat Castration-Resistant Prostate Cancer.
Prostatic Neoplasms
Activin A stimulates AKR1C3 expression and growth in human prostate cancer.
Prostatic Neoplasms
AKR1C2 and AKR1C3 mediated prostaglandin D2 metabolism augments the PI3K/Akt proliferative signaling pathway in human prostate cancer cells.
Prostatic Neoplasms
AKR1C3 (type 5 17?-hydroxysteroid dehydrogenase/prostaglandin F synthase): Roles in malignancy and endocrine disorders.
Prostatic Neoplasms
AKR1C3 as a potential target for the inhibitory effect of dietary flavonoids.
Prostatic Neoplasms
AKR1C3 expression in primary lesion rebiopsy at the time of metastatic castration-resistant prostate cancer is strongly associated with poor efficacy of abiraterone as a first-line therapy.
Prostatic Neoplasms
AKR1C3 Inhibition Therapy in Castration-Resistant Prostate Cancer and Breast Cancer: Lessons from Responses to SN33638.
Prostatic Neoplasms
AKR1C3 Inhibitor KV-37 Exhibits Antineoplastic Effects and Potentiates Enzalutamide in Combination Therapy in Prostate Adenocarcinoma Cells.
Prostatic Neoplasms
AKR1C3 mediates pan-AR antagonist resistance in castration-resistant prostate cancer.
Prostatic Neoplasms
AKR1C3 overexpression may serve as a promising biomarker for prostate cancer progression.
Prostatic Neoplasms
AKR1C3 promotes AR-V7 protein stabilization and confers resistance to AR-targeted therapies in advanced prostate cancer.
Prostatic Neoplasms
AKR1C3, a crucial androgenic enzyme in prostate cancer, promotes epithelial-mesenchymal transition and metastasis through activating ERK signaling.
Prostatic Neoplasms
Aldo-keto reductase family 1 member C3 (AKR1C3) is a biomarker and therapeutic target for castration-resistant prostate cancer.
Prostatic Neoplasms
Basal and Regulatory Promoter Studies of the AKR1C3 Gene in Relation to Prostate Cancer.
Prostatic Neoplasms
Canonical Androstenedione Reduction is the Predominant Source of Signalling Androgens in Hormone Refractory Prostate Cancer.
Prostatic Neoplasms
Consecutive Prostate Cancer Specimens Revealed Increased Aldo?Keto Reductase Family 1 Member C3 Expression with Progression to Castration-Resistant Prostate Cancer.
Prostatic Neoplasms
Correction: Overexpression of AKR1C3 significantly enhances human prostate cancer cells resistance to radiation.
Prostatic Neoplasms
Crystal structures of AKR1C3 containing an N-(aryl)amino-benzoate inhibitor and a bifunctional AKR1C3 inhibitor and androgen receptor antagonist. Therapeutic leads for castrate resistant prostate cancer.
Prostatic Neoplasms
Development of Novel AKR1C3 Inhibitors as New Potential Treatment for Castration-Resistant Prostate Cancer.
Prostatic Neoplasms
Development of Potent and Selective Indomethacin Analogues for the Inhibition of AKR1C3 (Type 5 17?-Hydroxysteroid Dehydrogenase/Prostaglandin F Synthase) in Castrate-Resistant Prostate Cancer.
Prostatic Neoplasms
Dual Inhibitory Action of a Novel AKR1C3 Inhibitor on Both Full-Length AR and the Variant AR-V7 in Enzalutamide Resistant Metastatic Castration Resistant Prostate Cancer.
Prostatic Neoplasms
Elevated AKR1C3 expression promotes prostate cancer cell survival and prostate cell-mediated endothelial cell tube formation: implications for prostate cancer progression.
Prostatic Neoplasms
Evaluation of genetic variations in the androgen and estrogen metabolic pathways as risk factors for sporadic and familial prostate cancer.
Prostatic Neoplasms
Impaired dihydrotestosterone catabolism in human prostate cancer: critical role of AKR1C2 as a pre-receptor regulator of androgen receptor signaling.
Prostatic Neoplasms
In vitro and in vivo characterisation of ASP9521: a novel, selective, orally bioavailable inhibitor of 17?-hydroxysteroid dehydrogenase type 5 (17?HSD5; AKR1C3).
Prostatic Neoplasms
Inhibition of AKR1C3 Activation Overcomes Resistance to Abiraterone in Advanced Prostate Cancer.
Prostatic Neoplasms
Inhibitors of type 5 17?-hydroxysteroid dehydrogenase (AKR1C3): Overview and structural insights.
Prostatic Neoplasms
Inhibitory Interplay of SULT2B1b Sulfotransferase with AKR1C3 Aldo-keto Reductase in Prostate Cancer.
Prostatic Neoplasms
Interaction between leukocyte aldo-keto reductase 1C3 activity, genotypes, biological, lifestyle and clinical features in a prostate cancer cohort from New Zealand.
Prostatic Neoplasms
Intracrine androgens and AKR1C3 activation confer resistance to enzalutamide in prostate cancer.
Prostatic Neoplasms
In vitro CAPE inhibitory activity towards human AKR1C3 and the molecular basis.
Prostatic Neoplasms
Knockdown of AKR1C3 exposes a potential epigenetic susceptibility in prostate cancer cells.
Prostatic Neoplasms
Mesoporous silica nanoparticles combined with AKR1C3 siRNA inhibited the growth of castration-resistant prostate cancer by suppressing androgen synthesis in vitro and in vivo.
Prostatic Neoplasms
Microarray analysis of survival pathways in human PC-3 prostate cancer cells.
Prostatic Neoplasms
Nuclear receptor ERR? contributes to castration-resistant growth of prostate cancer via its regulation of intratumoral androgen biosynthesis.
Prostatic Neoplasms
Overexpression of AKR1C3 significantly enhances human prostate cancer cells resistance to radiation.
Prostatic Neoplasms
Overexpression of aldo-keto reductase 1C3 (AKR1C3) in LNCaP cells diverts androgen metabolism towards testosterone resulting in resistance to the 5?-reductase inhibitor finasteride.
Prostatic Neoplasms
Polymorphisms in androgen metabolism genes with serum testosterone levels and prognosis in androgen-deprivation therapy.
Prostatic Neoplasms
Pomegranate polyphenols down-regulate expression of androgen-synthesizing genes in human prostate cancer cells overexpressing the androgen receptor.
Prostatic Neoplasms
Prostate cancer: ERG fusion and AKR1C3 form AR signalling feed-forward loop.
Prostatic Neoplasms
Reversal of Apalutamide and Darolutamide Aldo-Keto Reductase 1C3-Mediated Resistance by a Small Molecule Inhibitor.
Prostatic Neoplasms
Roles of aldo-keto reductase 1B10 and 1C3 and ATP-binding cassette transporter in docetaxel tolerance.
Prostatic Neoplasms
Screening baccharin analogs as selective inhibitors against type 5 17?-hydroxysteroid dehydrogenase (AKR1C3).
Prostatic Neoplasms
Screening, synthesis, crystal structure, and molecular basis of 6-amino-4-phenyl-1,4-dihydropyrano[2,3-c]pyrazole-5-carbonitriles as novel AKR1C3 inhibitors.
Prostatic Neoplasms
Selective AKR1C3 inhibitors do not recapitulate the anti-leukaemic activities of the pan-AKR1C inhibitor medroxyprogesterone acetate.
Prostatic Neoplasms
Selective inhibition of human type-5 17?-hydroxysteroid dehydrogenase (AKR1C3) by baccharin, a component of Brazilian propolis.
Prostatic Neoplasms
Simvastatin in combination with meclofenamic acid inhibits the proliferation and migration of human prostate cancer PC-3 cells via an AKR1C3 mechanism.
Prostatic Neoplasms
Steroidogenic Enzyme AKR1C3 Is a Novel Androgen Receptor-Selective Coactivator that Promotes Prostate Cancer Growth.
Prostatic Neoplasms
Targeting backdoor androgen synthesis through AKR1C3 inhibition: A presurgical hormonal ablative neoadjuvant trial in high-risk localized prostate cancer.
Prostatic Neoplasms
The Activity of SN33638, an Inhibitor of AKR1C3, on Testosterone and 17?-Estradiol Production and Function in Castration-Resistant Prostate Cancer and ER-Positive Breast Cancer.
Prostatic Neoplasms
The DHEA-sulfate depot following P450c17 inhibition supports the case for AKR1C3 inhibition in high risk localized and advanced castration resistant prostate cancer.
Prostatic Neoplasms
The interaction of CYP3A5 polymorphisms along the androgen metabolism pathway in prostate cancer.
Prostatic Neoplasms
The Steroidogenic Enzyme AKR1C3 Regulates Stability of the Ubiquitin Ligase Siah2 in Prostate Cancer Cells.
Prostatic Neoplasms
Tissue distribution of human AKR1C3 and rat homolog in the adult genitourinary system.
Proteinuria
Role of AKR1C3 in renal injury and glibenclamide is anti-inflammatory in preeclamptic rats.
Psoriasis
Aldo-Keto Reductase 1C3 Is Expressed in Differentiated Human Epidermis, Affects Keratinocyte Differentiation, and Is Upregulated in Atopic Dermatitis.
Skin Neoplasms
Aldo-keto reductase 1C3 is overexpressed in skin squamous cell carcinoma (SCC) and affects SCC growth via prostaglandin metabolism.
Small Cell Lung Carcinoma
Wentilactone A induces cell apoptosis by targeting AKR1C1 gene via the IGF-1R/IRS1/PI3K/AKT/Nrf2/FLIP/Caspase-3 signaling pathway in small cell lung cancer.
Squamous Cell Carcinoma of Head and Neck
AKR1C1 controls cisplatin-resistance in head and neck squamous cell carcinoma through cross-talk with the STAT1/3 signaling pathway.
Stomach Neoplasms
Screening and Survival Analysis of Hub Genes in Gastric Cancer Based on Bioinformatics.
Triple Negative Breast Neoplasms
Aryl hydrocarbon receptor counteracts pharmacological efficacy of doxorubicin via enhanced AKR1C3 expression in triple negative breast cancer cells.
Urinary Bladder Neoplasms
Aldo-keto reductase 1C1 induced by interleukin-1? mediates the invasive potential and drug resistance of metastatic bladder cancer cells.
Urinary Bladder Neoplasms
Bladder cancer risk and genetic variation in AKR1C3 and other metabolizing genes.
Urinary Bladder Neoplasms
Variation in Genes Encoding the Neuroactive Steroid Synthetic Enzymes 5?-Reductase Type 1 and 3?-Reductase Type 2 Is Associated With Alcohol Dependence.
Uterine Cervical Neoplasms
AKR1C1 Contributes to Cervical Cancer Progression via Regulating TWIST1 Expression.
Uterine Cervical Neoplasms
Clinical implications of aldo-keto reductase family 1 member C3 and its relationship with lipocalin 2 in cancer of the uterine cervix.
Wilms Tumor
Differential expression of type 2 3?/type 5 17?-hydroxysteroid dehydrogenase (AKR1C3) in tumors of the central nervous system.
Wilms Tumor
Expression of AKR1C3 in renal cell carcinoma, papillary urothelial carcinoma, and Wilms' tumor.
html completed